AustralieFrV1, PubMed, Checkpoint, bibRecord, 001096

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.

Identifieur interne : 001096 ( PubMed/Checkpoint ); précédent : 001095; suivant : 001097

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.

Auteurs : Mark A. Boyd [Australie] ; Janaki Amin [Australie] ; Patrick W G. Mallon [Irlande (pays)] ; Nagalingeswaran Kumarasamy [Inde] ; Johan Lombaard [Afrique du Sud] ; Robin Wood [Afrique du Sud] ; Ploenchan Chetchotisakd [Thaïlande] ; Praphan Phanuphak [Thaïlande] ; Lerato Mohapi [Afrique du Sud] ; Iskandar Azwa [Malaisie] ; Waldo H. Belloso [Argentine] ; Jean-Michel Molina [France] ; Jennifer Hoy [Australie] ; Cecilia L. Moore [Australie] ; Sean Emery [Australie] ; David A. Cooper [Australie]

Source :

The lancet. HIV [ 2352-3018 ] ; 2017.

RBID : pubmed:27815068

Descripteurs français

English descriptors

KwdEn :
- Absorptiometry, Photon, Adult, Anti-HIV Agents (administration & dosage), Anti-HIV Agents (adverse effects), Anti-HIV Agents (therapeutic use), Antiretroviral Therapy, Highly Active, Body Composition, CD4 Lymphocyte Count, Drug Therapy, Combination, Emtricitabine (administration & dosage), Emtricitabine (adverse effects), Female, HIV Infections (drug therapy), HIV Infections (metabolism), HIV Infections (virology), HIV Protease Inhibitors (administration & dosage), HIV Protease Inhibitors (adverse effects), HIV-1 (drug effects), HIV-Associated Lipodystrophy Syndrome (epidemiology), Humans, International Cooperation, Lamivudine (administration & dosage), Lamivudine (adverse effects), Lopinavir (administration & dosage), Lopinavir (adverse effects), Lopinavir (therapeutic use), Male, Raltegravir Potassium (administration & dosage), Raltegravir Potassium (adverse effects), Raltegravir Potassium (therapeutic use), Reverse Transcriptase Inhibitors (administration & dosage), Reverse Transcriptase Inhibitors (adverse effects), Reverse Transcriptase Inhibitors (therapeutic use), Ritonavir (administration & dosage), Ritonavir (adverse effects), Ritonavir (therapeutic use), Tenofovir (administration & dosage), Tenofovir (adverse effects), Viral Load.
MESH :
- chemical , administration & dosage : Anti-HIV Agents, Emtricitabine, HIV Protease Inhibitors, Lamivudine, Lopinavir, Raltegravir Potassium, Reverse Transcriptase Inhibitors, Ritonavir, Tenofovir.
- chemical , adverse effects : Anti-HIV Agents, Emtricitabine, HIV Protease Inhibitors, Lamivudine, Lopinavir, Raltegravir Potassium, Reverse Transcriptase Inhibitors, Ritonavir, Tenofovir.
- chemical , therapeutic use : Anti-HIV Agents, Lopinavir, Raltegravir Potassium, Reverse Transcriptase Inhibitors, Ritonavir.
- drug effects : HIV-1.
- drug therapy : HIV Infections.
- epidemiology : HIV-Associated Lipodystrophy Syndrome.
- metabolism : HIV Infections.
- virology : HIV Infections.
- Absorptiometry, Photon, Adult, Antiretroviral Therapy, Highly Active, Body Composition, CD4 Lymphocyte Count, Drug Therapy, Combination, Female, Humans, International Cooperation, Male, Viral Load.

Abstract

Lipoatrophy is one of the most feared complications associated with the use of nucleoside or nucleotide reverse transcriptase inhibitors (N[t]RTIs). We aimed to assess soft-tissue changes in participants with HIV who had virological failure of a first-line antiretroviral (ART) regimen containing a non-nucleoside reverse transcriptase inhibitor plus two N(t)RTIs and were randomly assigned to receive a second-line regimen containing a boosted protease inhibitor given with either N(t)RTIs or raltegravir.

DOI: 10.1016/S2352-3018(16)30189-8
PubMed: 27815068

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001359
to stream PubMed, to step Curation: 001337

Links to Exploration step

pubmed:27815068

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.</title>
<author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Adelaide, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. Electronic address: mark.boyd@adelaide.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of Adelaide, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia; The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name>
<affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name>
<affiliation wicri:level="1"><nlm:affiliation>UCD School of Medicine and Medical Science, Dublin, Ireland.</nlm:affiliation>
<country xml:lang="fr">Irlande (pays)</country>
<wicri:regionArea>UCD School of Medicine and Medical Science, Dublin</wicri:regionArea>
<wicri:noRegion>Dublin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name>
<affiliation wicri:level="1"><nlm:affiliation>YR Gaitonde Centre for AIDS Research and Education (YRG CARE), Chennai, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>YR Gaitonde Centre for AIDS Research and Education (YRG CARE), Chennai</wicri:regionArea>
<wicri:noRegion>Chennai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lombaard, Johan" sort="Lombaard, Johan" uniqKey="Lombaard J" first="Johan" last="Lombaard">Johan Lombaard</name>
<affiliation wicri:level="1"><nlm:affiliation>JOSHA Research, Bloemfontein, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>JOSHA Research, Bloemfontein</wicri:regionArea>
<wicri:noRegion>Bloemfontein</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wood, Robin" sort="Wood, Robin" uniqKey="Wood R" first="Robin" last="Wood">Robin Wood</name>
<affiliation wicri:level="1"><nlm:affiliation>Desmond Tutu HIV Foundation, Cape Town, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Desmond Tutu HIV Foundation, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chetchotisakd, Ploenchan" sort="Chetchotisakd, Ploenchan" uniqKey="Chetchotisakd P" first="Ploenchan" last="Chetchotisakd">Ploenchan Chetchotisakd</name>
<affiliation wicri:level="1"><nlm:affiliation>Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Srinagarind Hospital, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name>
<affiliation wicri:level="1"><nlm:affiliation>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mohapi, Lerato" sort="Mohapi, Lerato" uniqKey="Mohapi L" first="Lerato" last="Mohapi">Lerato Mohapi</name>
<affiliation wicri:level="4"><nlm:affiliation>Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg</wicri:regionArea>
<orgName type="university">Université du Witwatersrand</orgName>
<placeName><settlement type="city">Johannesbourg</settlement>
<region type="region" nuts="2">Gauteng</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Azwa, Iskandar" sort="Azwa, Iskandar" uniqKey="Azwa I" first="Iskandar" last="Azwa">Iskandar Azwa</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Malaya, Kuala Lumpur, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>University of Malaya, Kuala Lumpur</wicri:regionArea>
<wicri:noRegion>Kuala Lumpur</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Belloso, Waldo H" sort="Belloso, Waldo H" uniqKey="Belloso W" first="Waldo H" last="Belloso">Waldo H. Belloso</name>
<affiliation wicri:level="1"><nlm:affiliation>Coordinación de Investigación Clínica Académica en Latinoamérica (CICAL), Buenos Aires, Argentina.</nlm:affiliation>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Coordinación de Investigación Clínica Académica en Latinoamérica (CICAL), Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital St Louis, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital St Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hoy, Jennifer" sort="Hoy, Jennifer" uniqKey="Hoy J" first="Jennifer" last="Hoy">Jennifer Hoy</name>
<affiliation wicri:level="1"><nlm:affiliation>The Alfred Hospital and Monash University, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Alfred Hospital and Monash University, Melbourne, VIC</wicri:regionArea>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name>
<affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name>
<affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name>
<affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:27815068</idno>
<idno type="pmid">27815068</idno>
<idno type="doi">10.1016/S2352-3018(16)30189-8</idno>
<idno type="wicri:Area/PubMed/Corpus">001359</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001359</idno>
<idno type="wicri:Area/PubMed/Curation">001337</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001337</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001337</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001337</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.</title>
<author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Adelaide, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. Electronic address: mark.boyd@adelaide.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of Adelaide, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia; The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name>
<affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name>
<affiliation wicri:level="1"><nlm:affiliation>UCD School of Medicine and Medical Science, Dublin, Ireland.</nlm:affiliation>
<country xml:lang="fr">Irlande (pays)</country>
<wicri:regionArea>UCD School of Medicine and Medical Science, Dublin</wicri:regionArea>
<wicri:noRegion>Dublin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name>
<affiliation wicri:level="1"><nlm:affiliation>YR Gaitonde Centre for AIDS Research and Education (YRG CARE), Chennai, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>YR Gaitonde Centre for AIDS Research and Education (YRG CARE), Chennai</wicri:regionArea>
<wicri:noRegion>Chennai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lombaard, Johan" sort="Lombaard, Johan" uniqKey="Lombaard J" first="Johan" last="Lombaard">Johan Lombaard</name>
<affiliation wicri:level="1"><nlm:affiliation>JOSHA Research, Bloemfontein, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>JOSHA Research, Bloemfontein</wicri:regionArea>
<wicri:noRegion>Bloemfontein</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wood, Robin" sort="Wood, Robin" uniqKey="Wood R" first="Robin" last="Wood">Robin Wood</name>
<affiliation wicri:level="1"><nlm:affiliation>Desmond Tutu HIV Foundation, Cape Town, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Desmond Tutu HIV Foundation, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chetchotisakd, Ploenchan" sort="Chetchotisakd, Ploenchan" uniqKey="Chetchotisakd P" first="Ploenchan" last="Chetchotisakd">Ploenchan Chetchotisakd</name>
<affiliation wicri:level="1"><nlm:affiliation>Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Srinagarind Hospital, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name>
<affiliation wicri:level="1"><nlm:affiliation>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mohapi, Lerato" sort="Mohapi, Lerato" uniqKey="Mohapi L" first="Lerato" last="Mohapi">Lerato Mohapi</name>
<affiliation wicri:level="4"><nlm:affiliation>Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg</wicri:regionArea>
<orgName type="university">Université du Witwatersrand</orgName>
<placeName><settlement type="city">Johannesbourg</settlement>
<region type="region" nuts="2">Gauteng</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Azwa, Iskandar" sort="Azwa, Iskandar" uniqKey="Azwa I" first="Iskandar" last="Azwa">Iskandar Azwa</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Malaya, Kuala Lumpur, Malaysia.</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>University of Malaya, Kuala Lumpur</wicri:regionArea>
<wicri:noRegion>Kuala Lumpur</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Belloso, Waldo H" sort="Belloso, Waldo H" uniqKey="Belloso W" first="Waldo H" last="Belloso">Waldo H. Belloso</name>
<affiliation wicri:level="1"><nlm:affiliation>Coordinación de Investigación Clínica Académica en Latinoamérica (CICAL), Buenos Aires, Argentina.</nlm:affiliation>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Coordinación de Investigación Clínica Académica en Latinoamérica (CICAL), Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital St Louis, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital St Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hoy, Jennifer" sort="Hoy, Jennifer" uniqKey="Hoy J" first="Jennifer" last="Hoy">Jennifer Hoy</name>
<affiliation wicri:level="1"><nlm:affiliation>The Alfred Hospital and Monash University, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Alfred Hospital and Monash University, Melbourne, VIC</wicri:regionArea>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name>
<affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name>
<affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name>
<affiliation wicri:level="1"><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, University of New South Wales, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">The lancet. HIV</title>
<idno type="eISSN">2352-3018</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absorptiometry, Photon</term>
<term>Adult</term>
<term>Anti-HIV Agents (administration & dosage)</term>
<term>Anti-HIV Agents (adverse effects)</term>
<term>Anti-HIV Agents (therapeutic use)</term>
<term>Antiretroviral Therapy, Highly Active</term>
<term>Body Composition</term>
<term>CD4 Lymphocyte Count</term>
<term>Drug Therapy, Combination</term>
<term>Emtricitabine (administration & dosage)</term>
<term>Emtricitabine (adverse effects)</term>
<term>Female</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Infections (metabolism)</term>
<term>HIV Infections (virology)</term>
<term>HIV Protease Inhibitors (administration & dosage)</term>
<term>HIV Protease Inhibitors (adverse effects)</term>
<term>HIV-1 (drug effects)</term>
<term>HIV-Associated Lipodystrophy Syndrome (epidemiology)</term>
<term>Humans</term>
<term>International Cooperation</term>
<term>Lamivudine (administration & dosage)</term>
<term>Lamivudine (adverse effects)</term>
<term>Lopinavir (administration & dosage)</term>
<term>Lopinavir (adverse effects)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Male</term>
<term>Raltegravir Potassium (administration & dosage)</term>
<term>Raltegravir Potassium (adverse effects)</term>
<term>Raltegravir Potassium (therapeutic use)</term>
<term>Reverse Transcriptase Inhibitors (administration & dosage)</term>
<term>Reverse Transcriptase Inhibitors (adverse effects)</term>
<term>Reverse Transcriptase Inhibitors (therapeutic use)</term>
<term>Ritonavir (administration & dosage)</term>
<term>Ritonavir (adverse effects)</term>
<term>Ritonavir (therapeutic use)</term>
<term>Tenofovir (administration & dosage)</term>
<term>Tenofovir (adverse effects)</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Absorptiométrie photonique</term>
<term>Adulte</term>
<term>Agents antiVIH (administration et posologie)</term>
<term>Agents antiVIH (effets indésirables)</term>
<term>Agents antiVIH (usage thérapeutique)</term>
<term>Association de médicaments</term>
<term>Charge virale</term>
<term>Composition corporelle</term>
<term>Coopération internationale</term>
<term>Emtricitabine (administration et posologie)</term>
<term>Emtricitabine (effets indésirables)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Infections à VIH (métabolisme)</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Infections à VIH (virologie)</term>
<term>Inhibiteurs de la transcriptase inverse (administration et posologie)</term>
<term>Inhibiteurs de la transcriptase inverse (effets indésirables)</term>
<term>Inhibiteurs de la transcriptase inverse (usage thérapeutique)</term>
<term>Inhibiteurs de protéase du VIH (administration et posologie)</term>
<term>Inhibiteurs de protéase du VIH (effets indésirables)</term>
<term>Lamivudine (administration et posologie)</term>
<term>Lamivudine (effets indésirables)</term>
<term>Lipodystrophie associée au VIH (épidémiologie)</term>
<term>Lopinavir (administration et posologie)</term>
<term>Lopinavir (effets indésirables)</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Mâle</term>
<term>Numération des lymphocytes CD4</term>
<term>Raltégravir de potassium (administration et posologie)</term>
<term>Raltégravir de potassium (effets indésirables)</term>
<term>Raltégravir de potassium (usage thérapeutique)</term>
<term>Ritonavir (administration et posologie)</term>
<term>Ritonavir (effets indésirables)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Thérapie antirétrovirale hautement active</term>
<term>Ténofovir (administration et posologie)</term>
<term>Ténofovir (effets indésirables)</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Emtricitabine</term>
<term>HIV Protease Inhibitors</term>
<term>Lamivudine</term>
<term>Lopinavir</term>
<term>Raltegravir Potassium</term>
<term>Reverse Transcriptase Inhibitors</term>
<term>Ritonavir</term>
<term>Tenofovir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Emtricitabine</term>
<term>HIV Protease Inhibitors</term>
<term>Lamivudine</term>
<term>Lopinavir</term>
<term>Raltegravir Potassium</term>
<term>Reverse Transcriptase Inhibitors</term>
<term>Ritonavir</term>
<term>Tenofovir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Lopinavir</term>
<term>Raltegravir Potassium</term>
<term>Reverse Transcriptase Inhibitors</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term>
<term>Emtricitabine</term>
<term>Inhibiteurs de la transcriptase inverse</term>
<term>Inhibiteurs de protéase du VIH</term>
<term>Lamivudine</term>
<term>Lopinavir</term>
<term>Raltégravir de potassium</term>
<term>Ritonavir</term>
<term>Ténofovir</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term>
<term>Emtricitabine</term>
<term>Inhibiteurs de la transcriptase inverse</term>
<term>Inhibiteurs de protéase du VIH</term>
<term>Lamivudine</term>
<term>Lopinavir</term>
<term>Raltégravir de potassium</term>
<term>Ritonavir</term>
<term>Ténofovir</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV-Associated Lipodystrophy Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term>
<term>Inhibiteurs de la transcriptase inverse</term>
<term>Lopinavir</term>
<term>Raltégravir de potassium</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Lipodystrophie associée au VIH</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Absorptiometry, Photon</term>
<term>Adult</term>
<term>Antiretroviral Therapy, Highly Active</term>
<term>Body Composition</term>
<term>CD4 Lymphocyte Count</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>International Cooperation</term>
<term>Male</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Absorptiométrie photonique</term>
<term>Adulte</term>
<term>Association de médicaments</term>
<term>Charge virale</term>
<term>Composition corporelle</term>
<term>Coopération internationale</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Numération des lymphocytes CD4</term>
<term>Thérapie antirétrovirale hautement active</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lipoatrophy is one of the most feared complications associated with the use of nucleoside or nucleotide reverse transcriptase inhibitors (N[t]RTIs). We aimed to assess soft-tissue changes in participants with HIV who had virological failure of a first-line antiretroviral (ART) regimen containing a non-nucleoside reverse transcriptase inhibitor plus two N(t)RTIs and were randomly assigned to receive a second-line regimen containing a boosted protease inhibitor given with either N(t)RTIs or raltegravir.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27815068</PMID>
<DateCreated><Year>2016</Year>
<Month>11</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>07</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>07</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3018</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>4</Volume>
<Issue>1</Issue>
<PubDate><Year>2017</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>The lancet. HIV</Title>
<ISOAbbreviation>Lancet HIV</ISOAbbreviation>
</Journal>
<ArticleTitle>Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.</ArticleTitle>
<Pagination><MedlinePgn>e13-e20</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S2352-3018(16)30189-8</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S2352-3018(16)30189-8</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lipoatrophy is one of the most feared complications associated with the use of nucleoside or nucleotide reverse transcriptase inhibitors (N[t]RTIs). We aimed to assess soft-tissue changes in participants with HIV who had virological failure of a first-line antiretroviral (ART) regimen containing a non-nucleoside reverse transcriptase inhibitor plus two N(t)RTIs and were randomly assigned to receive a second-line regimen containing a boosted protease inhibitor given with either N(t)RTIs or raltegravir.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Of the 37 sites that participated in the randomised, open-label, non-inferiority SECOND-LINE study, eight sites from five countries (Argentina, India, Malaysia, South Africa, and Thailand) participated in the body composition substudy. All sites had a dual energy x-ray absorptiometry (DXA) scanner and all participants enrolled in SECOND-LINE were eligible for inclusion in the substudy. Participants were randomly assigned (1:1), via a computer-generated allocation schedule, to receive either ritonavir-boosted lopinavir plus raltegravir (raltegravir group) or ritonavir-boosted lopinavir plus two or three N(t)RTIs (N[t]RTI group). Randomisation was stratified by site and screening HIV-1 RNA. Participants and investigators were not masked to group assignment, but allocation was concealed until after interventions were assigned. DXA scans were done at weeks 0, 48, and 96. The primary endpoint was mean percentage and absolute change in peripheral limb fat from baseline to week 96. We did intention-to-treat analyses of available data. This substudy is registered with ClinicalTrials.gov, number NCT01513122.</AbstractText>
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Aug 1, 2010, and July 10, 2011, we recruited 211 participants into the substudy. The intention-to-treat population comprised 102 participants in the N(t)RTI group and 108 participants in the raltegravir group, of whom 91 and 105 participants, respectively, reached 96 weeks. Mean percentage change in limb fat from baseline to week 96 was 16·8% (SD 32·6) in the N(t)RTI group and 28·0% (37·6) in the raltegravir group (mean difference 10·2%, 95% CI 0·1-20·4; p=0·048). Mean absolute change was 1·04 kg (SD 2·29) in the N(t)RTI group and 1·81 kg (2·50) in the raltegravir group (mean difference 0·6, 95% CI -0·1 to 1·3; p=0·10).</AbstractText>
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our findings suggest that for people with virological failure of a first-line regimen containing efavirenz plus tenofovir and lamivudine or emtricitabine, the WHO-recommended switch to a ritonavir-boosted protease inhibitor plus zidovudine (a thymidine analogue nucleoside reverse transcriptase inhibitor) and lamivudine might come at the cost of peripheral lipoatrophy. Further study could help to define specific groups of people who might benefit from a switch to an N(t)RTI-sparing second-line ART regimen.</AbstractText>
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">The Kirby Institute and the Australian National Health and Medical Research Council.</AbstractText>
<CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyd</LastName>
<ForeName>Mark A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>University of Adelaide, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. Electronic address: mark.boyd@adelaide.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Amin</LastName>
<ForeName>Janaki</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mallon</LastName>
<ForeName>Patrick W G</ForeName>
<Initials>PW</Initials>
<AffiliationInfo><Affiliation>UCD School of Medicine and Medical Science, Dublin, Ireland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kumarasamy</LastName>
<ForeName>Nagalingeswaran</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>YR Gaitonde Centre for AIDS Research and Education (YRG CARE), Chennai, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lombaard</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>JOSHA Research, Bloemfontein, South Africa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wood</LastName>
<ForeName>Robin</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Desmond Tutu HIV Foundation, Cape Town, South Africa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chetchotisakd</LastName>
<ForeName>Ploenchan</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Phanuphak</LastName>
<ForeName>Praphan</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mohapi</LastName>
<ForeName>Lerato</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Azwa</LastName>
<ForeName>Iskandar</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>University of Malaya, Kuala Lumpur, Malaysia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Belloso</LastName>
<ForeName>Waldo H</ForeName>
<Initials>WH</Initials>
<AffiliationInfo><Affiliation>Coordinación de Investigación Clínica Académica en Latinoamérica (CICAL), Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molina</LastName>
<ForeName>Jean-Michel</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Hôpital St Louis, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hoy</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>The Alfred Hospital and Monash University, Melbourne, VIC, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moore</LastName>
<ForeName>Cecilia L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Emery</LastName>
<ForeName>Sean</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cooper</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>SECOND-LINE Study Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT01513122</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>11</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Lancet HIV</MedlineTA>
<NlmUniqueID>101645355</NlmUniqueID>
<ISSNLinking>2352-3018</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2T8Q726O95</RegistryNumber>
<NameOfSubstance UI="D019259">Lamivudine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>43Y000U234</RegistryNumber>
<NameOfSubstance UI="D000068898">Raltegravir Potassium</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>99YXE507IL</RegistryNumber>
<NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>G70B4ETF4S</RegistryNumber>
<NameOfSubstance UI="D000068679">Emtricitabine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015502" MajorTopicYN="N">Absorptiometry, Photon</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001823" MajorTopicYN="Y">Body Composition</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068679" MajorTopicYN="N">Emtricitabine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017320" MajorTopicYN="N">HIV Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D039682" MajorTopicYN="N">HIV-Associated Lipodystrophy Syndrome</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019259" MajorTopicYN="N">Lamivudine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068898" MajorTopicYN="N">Raltegravir Potassium</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>05</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>08</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>08</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>11</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>7</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>11</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27815068</ArticleId>
<ArticleId IdType="pii">S2352-3018(16)30189-8</ArticleId>
<ArticleId IdType="doi">10.1016/S2352-3018(16)30189-8</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Afrique du Sud</li>
<li>Argentine</li>
<li>Australie</li>
<li>France</li>
<li>Inde</li>
<li>Irlande (pays)</li>
<li>Malaisie</li>
<li>Thaïlande</li>
</country>
<region><li>Gauteng</li>
<li>Île-de-France</li>
</region>
<settlement><li>Johannesbourg</li>
<li>Paris</li>
</settlement>
<orgName><li>Université du Witwatersrand</li>
</orgName>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name>
</noRegion>
<name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name>
<name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name>
<name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name>
<name sortKey="Hoy, Jennifer" sort="Hoy, Jennifer" uniqKey="Hoy J" first="Jennifer" last="Hoy">Jennifer Hoy</name>
<name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name>
</country>
<country name="Irlande (pays)"><noRegion><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name>
</noRegion>
</country>
<country name="Inde"><noRegion><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name>
</noRegion>
</country>
<country name="Afrique du Sud"><noRegion><name sortKey="Lombaard, Johan" sort="Lombaard, Johan" uniqKey="Lombaard J" first="Johan" last="Lombaard">Johan Lombaard</name>
</noRegion>
<name sortKey="Mohapi, Lerato" sort="Mohapi, Lerato" uniqKey="Mohapi L" first="Lerato" last="Mohapi">Lerato Mohapi</name>
<name sortKey="Wood, Robin" sort="Wood, Robin" uniqKey="Wood R" first="Robin" last="Wood">Robin Wood</name>
</country>
<country name="Thaïlande"><noRegion><name sortKey="Chetchotisakd, Ploenchan" sort="Chetchotisakd, Ploenchan" uniqKey="Chetchotisakd P" first="Ploenchan" last="Chetchotisakd">Ploenchan Chetchotisakd</name>
</noRegion>
<name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name>
</country>
<country name="Malaisie"><noRegion><name sortKey="Azwa, Iskandar" sort="Azwa, Iskandar" uniqKey="Azwa I" first="Iskandar" last="Azwa">Iskandar Azwa</name>
</noRegion>
</country>
<country name="Argentine"><noRegion><name sortKey="Belloso, Waldo H" sort="Belloso, Waldo H" uniqKey="Belloso W" first="Waldo H" last="Belloso">Waldo H. Belloso</name>
</noRegion>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001096 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001096 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:27815068
   |texte=   Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:27815068" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie